Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Cerevel Therapeutics Holdings, Inc.

Market Cap 8.19B 7.06B 6.5B 6.1B 11.46B 774B 11.58B 76.81B 29.93B 379B 30.74B 30.09B 1,314B P/E Ratio 2022
-13.6x
P/E Ratio 2023 -15.9x
Enterprise Value 7.5B 6.46B 5.95B 5.59B 10.49B 709B 10.6B 70.29B 27.38B 347B 28.13B 27.53B 1,203B EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
93.64%
Yield 2022 *
-
Yield 2023 -
3 years 19.59
Extreme 19.59
44.99
5 years 12.01
Extreme 12.01
46.16
10 years 9
Extreme 9
46.16
Manager TitleAgeSince
President 59 01/08/2024
Chief Tech/Sci/R&D Officer 57 01/05/2019
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 20/01/2021
Director/Board Member 59 01/08/2024
Date Insider Type Main position Quantity % Market Cap.
01/08/24Issuer sale

Director

93,932 0.0516%
01/08/24Issuer sale

Head of Human Resources

800,774 0.4395%
01/08/24Issuer sale

Director

151,795 0.0833%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%-.--%-.--%+32.20% 8.19B
+0.74%-0.05%+61.29%+111.77% 54.54B
-1.22%+5.01%+43.38%+36.69% 43.86B
-1.43%+3.47%-15.83%-20.48% 22.63B
-1.99%-3.55%-5.97%+377.60% 20.7B
-0.53%+0.54%+16.19%-36.06% 15.84B
+1.83%-1.59%+9.82%-40.10% 14.83B
-1.70%-1.68%+24.79%+172.92% 13.1B
-5.17%+0.50%+21.80% - 12.66B
+0.29%+5.10%+75.82%+105.33% 11.56B
Average -0.83%+1.09%+23.13%+82.21% 21.79B
Weighted average by Cap. -0.63%+0.71%+30.48%+85.94%

Financials

2022 2023
Net sales - -
Net income -352M -303M -279M -262M -492M -33.23B -497M -3.3B -1.28B -16.27B -1.32B -1.29B -56.4B -433M -373M -343M -323M -606M -40.92B -612M -4.06B -1.58B -20.04B -1.62B -1.59B -69.45B
Net Debt -523M -451M -415M -390M -732M -49.47B -740M -4.91B -1.91B -24.23B -1.96B -1.92B -83.95B -695M -599M -552M -518M -973M -65.75B -983M -6.52B -2.54B -32.2B -2.61B -2.55B -112B
Logo Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Employees
355
  1. Stock Market
  2. Stocks
  3. CERE Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!